Using Facebook For Good
One of the most common questions we are asked here at AIM by patients, families, and friends is How can…
09/26/2021
Using Facebook For Good
One of the most common questions we are asked here at AIM by patients, families, and friends is How can…
|
09/24/2021
FDA Takes Steps Aimed at Improving Quality, Safety and Efficacy of Sunscreens
For Immediate Release: September 24, 2021 (repost from FDA) The U.S. Food and Drug Administration today took steps aimed at…
|
09/24/2021
International Survivor Spotlight: José Correia, Portugal
By Mara Klecker José Correia’s melanoma diagnosis was nearly a quarter-century ago, but he is committed to spreading awareness about…
|
|
09/24/2021
Making the Cut For Melanoma: A Mom’s Motivation
By Mara Klecker As a social service director working in long-term care, Traci Cunningham made a promise to her…
|
|
09/24/2021
President’s Letter | September 2021
From the Desk of Samantha Guild As I reviewed the articles for this month’s newsletter, I thought about the fact…
|
09/24/2021
What is Translational Medicine?
By Maria Libera Ascierto, MS, PhD Associate Professor Translational Cancer Immunology Director “The Rosalie and Harold R Brown Cancer Immunotherapy”…
|
09/24/2021
Melanoma by the State: Oregon
Let’s start with some fun facts about Oregon: Oregon boasts the deepest lake in the U.S., Crater Lake, with a…
|
09/24/2021
Motherhood and Melanoma: Raleigh Minning, Stage III Melanoma Survivor
By Mara Klecker One of the only times Raleigh Minning cried during her melanoma journey was when she thought of…
|
09/20/2021
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
|
|
09/20/2021
USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
|
|
Recent Posts
Jun. 05, 2026
Fifth Annual Evening in Memory of Valerie Guild
Jun. 05, 2026
Results for darovasertib in combination with crizotinib in first line HLA*A2:01-negative metastatic uveal melanoma met the study’s primary objective
Jun. 05, 2026
Encouraging results with anzutresgene autoleucel in patients with uveal melanoma and other melanoma subtypes
Jun. 05, 2026
Promising early results with imneskibart, low-dose subcutaneous IL-2, and nivolumab in patients who do not respond to or who relapse after receiving combination checkpoint inhibitors
Jun. 05, 2026